Is there a Bearish outlook for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) this week?

September 16, 2018 - By Russell Jones

Investors sentiment increased to 1.53 in 2018 Q2. Its up 0.57, from 0.96 in 2018Q1. It is positive, as 10 investors sold Vanda Pharmaceuticals Inc. shares while 33 reduced holdings. 18 funds opened positions while 48 raised stakes. 47.64 million shares or 3.78% more from 45.90 million shares in 2018Q1 were reported.
Rothschild Asset Mngmt Inc invested in 0.09% or 450,021 shares. Century Incorporated accumulated 60,106 shares. Parametric Associates Ltd Liability accumulated 0% or 17,619 shares. 538 were reported by Glenmede Na. Hbk Investments L P invested in 191,324 shares. Weiss Multi reported 39,358 shares. Bluemountain Mngmt Lc reported 0.02% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Metropolitan Life holds 0% or 17,187 shares. Quantitative Investment Mngmt Ltd Com has 12,300 shares. Schwab Charles Investment Mgmt holds 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 391,939 shares. D E Shaw owns 340,896 shares or 0.01% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Brandywine Investment Mngmt Limited Liability Corporation has 0.01% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 47,282 shares. Proshare Advsrs Ltd Limited Liability Company has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Minnesota-based Foundry Prns Limited Liability has invested 0.04% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 3 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Vanda Pharmaceuticals had 3 analyst reports since May 23, 2018 according to SRatingsIntel. Below is a list of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings and price target changes.

14/09/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $30 Initiates Coverage On
23/08/2018 Broker: Cantor Fitzgerald Rating: Neutral New Target: $26 Initiates Coverage On
23/05/2018 Broker: Citigroup Rating: Buy Initiates Coverage On

The stock increased 7.57% or $1.4 during the last trading session, reaching $19.9. About 1.06 million shares traded or 109.34% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 6.96% since September 16, 2017 and is uptrending. It has underperformed by 8.66% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $1.04 billion. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It has a 737.04 P/E ratio. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

More news for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were recently published by:, which released: “HETLIOZ driving study demonstrates no impairment in next morning performance” on September 13, 2018.‘s article titled: “Premarket analyst action – healthcare” and published on August 23, 2018 is yet another important article.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.